Gabapentin Capsule
Product Images NDC 76420-020

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 76420-020). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Asclemed Usa, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image (300mg)

The text describes various packages of Gabapentin Capsules, USP 300mg manufactured for Cipla USA, Inc. The packages have different quantities (30, 60, 90, or 240). Each package has a unique NDC number, lot number, and batch number. The capsules are yellow and are RX drugs that require a prescription to dispense. The caution message from the package insert warns about the prohibition of dispensing without prescription and the need to store at a certain temperature range.*

FDA Label Image

Image (D3fd11fe 4d3f 4002 8f9e 42cc12b4252d 01)

This is a table detailing the recommended Gabapentin dosage based on renal function. The table lists the total daily dose range in milligrams (mg) for patients with varying degrees of renal function based on their creatinine clearance. Patients on hemodialysis require additional supplemental doses. The table also provides dosage frequency information (e.g. TID, BID, QD) and a formula for estimating creatinine clearance using the Cockcroft and Gault equation.*

FDA Label Image

Image (D3fd11fe 4d3f 4002 8f9e 42cc12b4252d 03)

This appears to be a table showing the risk of antiepileptic drugs for different indications, including epilepsy and psychiatric disorders. The table shows the number of patients with events per 1,000 patients for both placebo and drug groups, as well as the relative risk and risk difference.*

FDA Label Image

Image (D3fd11fe 4d3f 4002 8f9e 42cc12b4252d 04)

This is a table which shows the percentage of adverse reactions in a group of people who took Gabapentin and another group who took Placebo in Pooled Placebo-Controlled Trials in Postherpetic Neuralgia. The table categorizes the adverse reactions into different systems such as Body as a whole, Digestive system, Metabolic and Nutritional disorders, Nervous system, Respiratory system, Special senses, and reports on different adverse reactions in each group.*

FDA Label Image

Image (D3fd11fe 4d3f 4002 8f9e 42cc12b4252d 05)

This is a table showing adverse reactions observed in epilepsy patients of age greater than 12 years in pooled placebo-controlled add-on trials. The table has columns for Gabapentin (N=543) and Placebo (N=378) and lists various adverse reactions and their percentage occurrence. The adverse reactions are categorised under different organ systems such as Body As A Whole, Cardiovasoular, Digestive System, Nervous System, Respiratory System, Skin, and Appendages, Urogenttal System and Special Senses. In addition to this, the table also provides additional information about certain adverse reactions such as Amblyopia.*

FDA Label Image

Image (D3fd11fe 4d3f 4002 8f9e 42cc12b4252d 06)

This is a table that shows the adverse reactions observed in a placebo-controlled add-on trial of Gabapentin in pediatric epilepsy patients between the ages of 3 and 12. There were 110 patients who received Gabapentin and 128 who received placebo as part of their anti-epileptic drug therapy. The table shows the percentage of patients who experienced each type of adverse reaction for each group, including body weakness, viral infection, fever, increased weight, fatigue, nausea and vomiting, somnolence, hostility, emotional lability, dizziness, hyperkinesia, bronchitis, and respiratory infection.*

FDA Label Image

Image (D3fd11fe 4d3f 4002 8f9e 42cc12b4252d 07)

FDA Label Image

Image (D3fd11fe 4d3f 4002 8f9e 42cc12b4252d 08)

This is a table presenting information on controlled studies that were conducted on Gabapentin, a medication used to treat pain associated with nerve damage. The table includes details on the duration of the studies, the dosages of Gabapentin administered to patients, and the number of patients receiving Gabapentin and a placebo. The medication was given in three divided doses per day.*

FDA Label Image

Image (D3fd11fe 4d3f 4002 8f9e 42cc12b4252d 09)

FDA Label Image

Image (D3fd11fe 4d3f 4002 8f9e 42cc12b4252d 10)

FDA Label Image

Image (D3fd11fe 4d3f 4002 8f9e 42cc12b4252d 11)

FDA Label Image

Image (D3fd11fe 4d3f 4002 8f9e 42cc12b4252d 12)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.